ESTA — Establishment Labs Holdings Inc.

Establishment Labs Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $64.6 million, up 45.2% year-over-year.
• 2025 Total Revenue: $211.1 million, a 27.2% increase from 2024.
• U.S. Motiva Revenue: $17.3 million in Q4; total for 2025 was $45.6 million.
• Gross Margin: 70.5% in Q4, consistent with previous quarters, with a 330 basis point increase for the year.
• Net Loss: $3.9 million in Q4, down 79% from Q4 2024.
• Adjusted EBITDA: Positive $5.5 million in Q4, a significant improvement from a loss of $13.1 million in the previous year.
• Cash Position: Ended 2025 with $75.6 million, indicating no immediate need for additional capital.

2. Strategic Updates and Business Highlights

• Market Position: Established a 20% market share in the U.S. breast augmentation market within one year of entry.
• Innovation Focus: Continued investment in R&D has led to differentiated products, particularly the Motiva implants and the new Preserve minimally invasive augmentation procedure.
• Surgeon Engagement: High interest from plastic surgeons, with 88% indicating they use or are interested in Motiva, and many patients requesting it by name.
• Global Expansion: Strong performance in Europe and Latin America, with over 20% growth in European direct markets for three consecutive quarters.
• New Leadership: Transition of CFO Raj Denhoy to SVP Global Strategy, with Cassandra Harris appointed as the new CFO to support growth initiatives.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: $264 million to $266 million, representing a growth of 25% to 26% over 2025.
• U.S. Sales Growth: Expected to exceed 30% of overall sales, up from approximately 22% in 2025.
• Gross Margin Expectations: Anticipated increase of 200 to 300 basis points in 2026.
• Cash Flow: Projected to be cash flow positive in 2026, with significant earnings expected in 2027.

4. Bad News, Challenges, or Points of Concern

• Market Volatility: Potential fluctuations in distributor markets could impact revenue consistency.
• Regulatory Approval: The timeline for FDA approval of Motiva for reconstruction remains uncertain, which could delay market expansion.
• Operational Challenges: Need for specialized sales representatives for the reconstruction market may complicate the launch strategy.
• Competitive Landscape: Continued competition in the breast aesthetics market could pressure pricing and market share.

5. Notable Q&A Insights

• Minimally Invasive Portfolio: Positive early feedback on Preserve suggests it could significantly expand the market for breast augmentation, with potential for it to represent 50% of U.S. revenues by 2027-2028.
• Sales Force Expansion: Plans to increase the U.S. sales team by 30% with experienced representatives, enhancing market penetration.
• China Market: Management is optimistic about growth in China, citing recent improvements in distributor performance and market interest.
• Revenue Growth Drivers: Future growth is expected to come primarily from volume increases rather than price increases, with a focus on deepening penetration in existing accounts.

Overall, Establishment Labs demonstrated strong financial performance in Q4 2025, with significant growth prospects driven by innovative products and strategic market positioning, despite facing some regulatory and competitive challenges.